Draft:Annovis Bio
Description of a biotechnology company
From Wikipedia, the free encyclopedia
Annovis Bio, Inc. is a biotechnology company focused on developing treatments for neurodegenerative disorders such as Alzheimer's disease (AD) and Parkinson's disease (PD).[1] The company is headquartered in Malvern, Pennsylvania and was founded in 2008 by Dr. Maria Maccecchini. Annovis Bio is publicly listed on the New York Stock Exchange (NYSE) under the ticker symbol ANVS.[2] Its lead drug candidate buntanetap (previously known as posiphen) is an investigational treatment for Alzheimer's and Parkinson's in Phase 3 clinical development.[3]
 | Review waiting, please be patient.
This may take 2 months or more, since drafts are reviewed in no specific order. There are 3,483 pending submissions waiting for review.
Where to get help
How to improve a draft
You can also browse Wikipedia:Featured articles and Wikipedia:Good articles to find examples of Wikipedia's best writing on topics similar to your proposed article. Improving your odds of a speedy review To improve your odds of a faster review, tag your draft with relevant WikiProject tags using the button below. This will let reviewers know a new draft has been submitted in their area of interest. For instance, if you wrote about a female astronomer, you would want to add the Biography, Astronomy, and Women scientists tags. Editor resources
Reviewer tools
|
Submission declined on 4 March 2026 by AllWeKnowOfHeaven (talk).
Where to get help
How to improve a draft
You can also browse Wikipedia:Featured articles and Wikipedia:Good articles to find examples of Wikipedia's best writing on topics similar to your proposed article. Improving your odds of a speedy review To improve your odds of a faster review, tag your draft with relevant WikiProject tags using the button below. This will let reviewers know a new draft has been submitted in their area of interest. For instance, if you wrote about a female astronomer, you would want to add the Biography, Astronomy, and Women scientists tags. Editor resources
This draft has been resubmitted and is currently awaiting re-review. |  |
History
The company's investigational drug, buntanetap, was discovered through a program funded by the National Institutes of Health (NIH) and later licensed to Axonyx. After Axonyx merged with TorreyPines Therapeutics, Dr. Maccecchini acquired the rights to buntanetap and continued its development through a newly founded company - originally named QR Pharma - which was established in 2008.[4] In 2019, QR Pharma was renamed Annovis Bio, and in January 2020 the company completed an initial public offering (IPO) on the NYSE, raising approximately $13.8 million.[5] Dr. Maccecchini has served as the company's Chief Executive Officer (CEO) since its inception.
Scientific approach
Annovis Bio's research is based on the hypothesis that the inhibition of overproduction of multiple neurotoxic proteins, which are prone to aggregation, might slow the progression of neurodegenerative diseases.[6][7] Neurodegenerative disorders like Alzheimer's and Parkinson's are hypothesized to be driven by the accumulation of misfolded or aggregating proteins, including amyloid-beta, tau, alpha-synuclein, and TDP-43, that can disrupt communication between cells, impair neuronal function, cause inflammation, and ultimately lead to death of nerve cells.[8][9]
Lead drug candidate
Buntanetap (previously known as posiphen) is an orally administered small molecule and a (+)-enantiomer of phenserine, but unlike phenserine it does not inhibit acetylcholinesterase.[3] Buntanetap is hypothesized to act by strengthening the interaction between mRNAs of neurotoxic proteins and iron regulatory protein 1 (IRP1), preventing their translation (essential part of protein synthesis) by ribosomes.[10][11] Through this mechanism, the drug is believed to simultaneously inhibit the synthesis of multiple proteins that aggregate in neurodegenerative diseases. Preclinical and early clinical studies have shown an association between treatment with buntanetap and reduced levels of amyloid precursor protein (APP) and amyloid-beta,[12][13] tau,[14] alpha-synuclein,[15] and TDP-43,[16] as well as huntingtin and prion protein.[17][18]
Clinical development
Phase 1 and 2 studies in humans have assessed buntanetap's safety, tolerability, and effects on biomarkers in early Alzheimer's and Parkinson's patients.[19][20][21] In a Phase 2/3 trial, buntanetap was tested in mild-to-moderate Alzheimer's patients for 3 months.[22] The study did not meet its primary endpoints, but the company reported an improvement in patients with mild-stage disease compared to placebo as part of a secondary analysis. In a Phase 3 trial, buntanetap was tested in early Parkinson's patients for 6 months.[23][24][25] The company reported improved cognitive function in patients receiving buntanetap compared to placebo and improved motor function in certain subpopulations. In 2025, Annovis Bio launched a Phase 3 trial of buntanetap in early Alzheimer's patients to evaluate clinical efficacy and safety.[26][27] The company also began an open-label extension study in Parkinson's patients in 2026 to gather long-term data.[28] As of 2026, buntanetap remains an investigational drug and has not received regulatory approval for any indication.
Wikipedia articles must be written neutrally in a formal, impersonal, and dispassionate way. They should not read like a blog post, advertisement, or fan page. Rewrite the draft to remove:
Instead, only summarize in your own words a range of independent, reliable, published sources that discuss the subject.
If you have a conflict of interest (e.g. you are the subject, an employee, or a relative) or are being paid to edit, you must disclose this to comply with Wikipedia's Terms of Use.